Zimbabwe has turned down a significant US healthcare agreement worth $367m (272 million pounds) spanning five years due to the United States' insistence on sensitive biological samples.
This rejection came to light after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
An official spokesman has since stated that the United States was requesting genetic material for scientific study and commercial gain but was unwilling to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for continued dialogue to find a deal suitable to all parties so the country's vital HIV programme can continue.
Wider Background
This development follows a comparable case in neighbouring Kenya, where a high court suspended a related deal with the US following concerns were raised about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing direct bilateral agreements to boost openness and responsibility.
Based on statements, 16 African countries have to date signed similar health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to share its genetic material and health information indefinitely, without any corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the raw materials for scientific discovery with no certainty that the final treatments would be available to our citizens should a new pandemic emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining structures previously established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This system is designed to ensure that when a country contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage ongoing dialogue with our American counterparts on how future co-operation could be structured in a manner that respects the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but suggested that talks must proceed considering a large portion of the nation's HIV programmes relied on international support.
"If technical issues exist, including those relating to data governance or agreement terms, these can often be resolved through detailed discussion and mutually agreed protections," the group said.
The halted deal emphasises the continuing tensions between accepting crucial international aid and safeguarding national sovereignty in an increasingly data-driven world.